Safety, risks & the clinical route
This app informs — it does not advertise. Here you find the honest classification of the risks that marketing often omits.
“For Research Use Only” is a legal shell, not a safety seal.
This label keeps products outside medicines regulation. It says nothing about purity, identity, sterility or suitability for humans. On the gray market it often serves to hand out prescription-only or wholly unapproved substances without medical oversight. What matters is always the substance’s real regulatory status — not the label.
Concrete risks of buying on the gray market
Unknown quality
Active-ingredient content, purity and sterility are unverified in “research” vials. Contamination and wrong amounts are documented.
Counterfeits
Especially for popular metabolic drugs, counterfeit and mislabelled products are a known, real problem.
No oversight
Without a medical indication, counselling and follow-up, contraindications and interactions go undetected.
Unapproved substances
Some substances (e.g. in clinical trials) have no established safety profile for use outside studies.
Legal risks
Buying, importing and possessing unapproved substances can be legally problematic depending on the country.
Deceptive anecdotes
Forum reports and social media do not replace controlled studies — they are anecdotal and not representative.
Before any use even comes into question
Not a guide, but a classification: these are the points that matter most given the current evidence — and that show why this decision belongs with a doctor. Deliberately without dosing.
Medical supervision is the real safety factor
For every substance described here, safety is decided not by the molecule alone but by the framework: medical indication, counselling, checking contraindications and interactions, and follow-up. This very framework is entirely missing when buying on the gray market. Before any use even comes into question, the question “is this sensible and safe for me?” belongs in expert hands — not in self-management.
“For Research Use Only” is no safety seal
This label keeps a product outside medicines control. It says nothing about identity, purity, sterility or suitability for humans. What matters is always the substance’s real regulatory status, not the label — and that ranges from “approved, prescription-only” through “legitimate only in studies” to “not approved for humans”.
The large-scale copying of GLP-1 is over
In the US, pharmacy compounding of semaglutide and tirzepatide was only allowed while an official supply shortage existed. The FDA declared these shortages over in late 2024/early 2025; the transition periods for compounders expired in 2025, and lawsuits against this failed in court. What is now offered online as cheap “compounded” or “research” GLP-1 therefore clearly stands outside regular, verified supply.
Counterfeits are documented by authorities — not a cliché
For GLP-1 products, counterfeits are repeatedly documented by authorities: the EMA warned of counterfeit pens labelled as Ozempic in the European supply chain. The WHO issued a global product warning in 2024, and Germany’s BfArM reported counterfeits that contained the insulin glargine instead of semaglutide — a potentially life-threatening mix-up. Counterfeit needles without confirmed sterility were also found.
Self-drawn vials are a documented source of error
From 2017 onwards, US poison control centres recorded several thousand reports about GLP-1 drugs, a large share due to usage or dosing errors; by 2024 cases continued to rise sharply. A key reason: loose “compounded” vials lack the safety mechanisms of an industrial pre-filled pen. Inconsistent units of measure and missing pharmaceutical advice led, in documented cases, to substantial overdoses.
Eye warning sign under GLP-1: sudden vision loss
The EMA safety committee (PRAC) classified the rare eye disease NAION (non-arteritic anterior ischemic optic neuropathy) in 2025 as a very rare side effect of semaglutide (up to 1 in 10,000 users) and recommended adding it to the product information. NAION appears as sudden, often painless vision loss and can be permanent. If such a symptom occurs during treatment, it is an emergency sign — a further reason not to use such substances without medical supervision.
Always inform before surgery and endoscopy
Because GLP-1 and GIP/GLP-1 drugs slow gastric emptying, stomach contents can remain longer — relevant to the aspiration risk under anaesthesia or endoscopy. Professional societies published a joint guideline on this in 2024. Whether and how the medicine is adjusted around a procedure is an individual medical decision. Anyone planning a procedure with anaesthesia or a gastroscopy should be sure to tell the treatment team about the use in advance.
A positive study result is no safety seal
Substances like retatrutide show pronounced effects in ongoing studies but remain unapproved. “Research” peptides like BPC-157, TB-500 or CJC-1295/ipamorelin have no established human safety profile; for CJC-1295 an injectable batch was even recalled in 2025 for lack of sterility. Anyone obtaining such substances outside studies bypasses regulatory review entirely.
Warning signs — seek medical help immediately
If the following signs occur during use (even medically supervised), that is a reason for immediate medical help — in an emergency, the emergency services.
- Sudden, often painless vision loss or rapidly fading sight in one eye (possible NAION warning sign).
- Persistent vomiting, severe or cramping abdominal pain, a strongly bloated abdomen and absent bowel movements (possible signs of bowel obstruction/ileus).
- Severe, persistent upper-abdominal pain radiating to the back, with nausea/vomiting (suspected pancreatitis).
- Signs of low blood sugar such as trembling, cold sweat, racing heart and confusion (especially with insulin or certain diabetes tablets).
- Markedly reduced urine output, pronounced weakness or light-headedness with persistent vomiting/diarrhoea (possible dehydration/kidney strain).
- A palpable lump in the neck, persistent hoarseness or difficulty swallowing.
- Signs of an allergic reaction up to anaphylaxis (shortness of breath, swelling of the face/throat, circulatory weakness) after using an unapproved peptide.
- High fever, redness or pus at an injection site (possible infection from non-sterile products).
Who must be especially careful
Circumstances in which the risk outweighs the benefit or a particularly careful medical assessment is needed — an incomplete, general overview.
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN-2 — contraindication for GLP-1/GIP-GLP-1 drugs (US boxed warning).
- Pregnancy and breastfeeding — incretin drugs and GHRH analogues not recommended or contraindicated.
- Previous pancreatitis or known gallbladder disease — increased risk, medical assessment needed.
- Active cancers and disorders of the hypothalamic-pituitary axis — contraindication for tesamorelin (GHRH analogue).
- Treatment with insulin or sulfonylureas — increased risk of low blood sugar, medical adjustment of concomitant medication needed.
- Pre-existing gastric-emptying disorder (gastroparesis) — increased risk with drugs that slow gastric emptying.
- Planned surgery with anaesthesia or gastroscopy — raise it in advance with the doctor/anaesthetist (aspiration risk).
- Existing diabetic retinopathy — particular medical caution with IGF-1-raising drugs (e.g. tesamorelin).
The legitimate route runs through medical supervision
For several of the indications described here (e.g. weight regulation, type 2 diabetes), there are approved medicines that are prescribed and supervised by a doctor. That means: verified quality, an appropriate indication, counselling about risks and monitoring of the course.
- Talk to a doctor about your concern — a GP practice, endocrinology or specialised clinics are good points of contact.
- Have it assessed whether treatment is sensible and safe and which approved option is suitable.
- Obtain prescription-only medicines exclusively from a regular pharmacy on prescription.
- For acute complaints or side effects: seek medical help, in an emergency the emergency services.
Why this app deliberately offers no dose calculator
Reconstitution and half-life calculators are not knowledge but the executing step before the injection. We expose how such tools work on the gray market.
More background? Read the fundamentals or look at the profiles.